DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Loeys-Dietz syndrome 6 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLoeys-Dietz syndrome 6 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for loeys-dietz syndrome 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SMAD family member 2 (SMAD2) — SMAD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet -drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZVQ · 2.03 Å · ligand D(-)-TARTARIC ACID (TAR). Experimental structure, not a prediction.
What the evidence adds up to
In a 2014 study of 23 Loeys-Dietz syndrome patients, including six with novel TGF-β receptor mutations, circulating outgrowth endothelial cells were isolated and compared to age- and sex-matched healthy controls. Microarray analysis and quantitative PCR showed altered expression of several genes in the TGF-β pathway, particularly those affecting bone morphogenic protein signalling, including BMP2, BMP4 and BMPR1A. The BMP antagonist Gremlin-1 showed the most prominent up-regulation, confirmed at the protein level by immunoblotting of patient cells. Immunohistochemistry found abundant Gremlin-1 protein in endothelial cells and smooth muscle cells within the arterial media, and plasma levels of Gremlin-1 were significantly elevated in LDS patients compared to healthy controls. The authors suggested these findings might open avenues for understanding pathogenesis and developing serological methods for early disease detection.
A 2017 Spanish case series described four familial cases across three generations, all with severe aortic dilatation, and discussed diagnostic aspects, surgical indications and follow-up guidelines. A 2022 report followed a 27-year-old woman with LDS over a ten-year surgical course, documenting ectopic arterial enlargement and its temporal changes on computed tomography, along with appearance and pathology findings at surgery.
No drug treatment was tested in any of these studies. The 2014 work identified Gremlin-1 as a potential biomarker but did not propose or test any intervention. What remains missing is any clinical trial of a drug aimed at reducing aortic aneurysm progression in Loeys-Dietz syndrome, any validated biomarker that has been prospectively tested for early detection, and any patient stratification strategy that links molecular findings to surgical outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2014 · 18 citations · open access
Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
AbstractBACKGROUNDS: The Loeys-Dietz syndrome (LDS) is an inherited connective tissue disorder caused by mutations in the transforming growth factor β (TGF-β) receptors TGFBR1 or TGFBR2. Most patients with LDS develop severe aortic aneurysms resulting in early need of surgical intervention. In order to gain further insight into the pathophysiology of the disorder, we investigated circulating outgrowth endothelial cells (OEC) from the peripheral blood of LDS patients from a cohort of 23 patients including 6 patients with novel TGF-β receptor mutations. METHODS AND RESULTS: We performed gene expression profiling of OECs using microarray analysis followed by quantitative PCR for verification of gene expression. Compared to OECs of age- and sex-matched healthy controls, OECs isolated from three LDS patients displayed altered expression of several genes belonging to the TGF-β pathway, especially those affecting bone morphogenic protein (BMP) signalling including BMP2, BMP4 and BMPR1A. Gene expression of BMP antagonist Gremlin-1 (GREM1) showed the most prominent up-regulation. This increase was confirmed at the protein level by immunoblotting of LDS-OECs. In immunohistochemistry, abundant Gremlin-1 protein expression could be verified in endothelial cells as well as smooth muscle cells within the arterial media. Furthermore, Gremlin-1 plasma levels of LDS patients were significantly elevated compared to healthy control subjects. CONCLUSIONS: These findings open new avenues in the understanding of the pathogenesis of Loeys-Dietz syndrome and the development of new diagnostic serological methods for early disease detection.
Archivos Argentinos de Pediatria · 2017 · 1 citations · open access
Síndrome de Loeys-Dietz, 3 generaciones, 4 casos familiares
AbstractEl sndrome de Loeys-Dietz es una enfermedad gentica autosmica dominante caracterizada por aneurismas articos, tortuosidad arterial generalizada, hipertelorismo y vula bfida o paladar hendido. La complicacin cardiovascular ms grave es la diseccin artica. Se presentan cuatro casos familiares de este sndrome en tres generaciones, todos con dilatacin artica grave, y se describen sus aspectos diagnsticos, indicacin y tratamiento quirrgico, como as tambin pautas de seguimiento.
Research Square · 2022 · 0 citations · open access
Ectopic Vasodilation of a young woman with Loeys-Dietz syndrome in 10 years
AbstractAbstract We report the 10-year surgical course of a 27-year-old young woman who underwent two surgeries s after being diagnosed with Loeys-Dietz syndrome (LDS). As previously reported, this case showed ectopic arterial enlargement, and we can follow its temporal changes over a 10-year period. We described computed tomography (CT) changes over time and the appearance and pathology findings in surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
